Insphero liver hanging
Nettet1. feb. 2024 · Insphero incorporates primary hepatocytes, Kupffer cells, and sinusoidal endothelial cells to recapitulate the native liver microenvironment in spheroid-based models . Ideal for long-term treatment regimens needed to gauge the efficacy of compounds, these models are geared for use in high-throughput screening. NettetInSphero 6 396 følgere på LinkedIn. Innovate Investigate Discover Together InSphero provides superior biological relevance to in vitro testing with easy-to-use …
Insphero liver hanging
Did you know?
Nettet19. okt. 2024 · Here, a scalable, gravity-driven microfluidic system featuring 3D microtissues (MTs) that represent different organs for the prediction of drug–drug interactions is used. Human liver microtissues (hLiMTs) are combined with tumor microtissues (TuMTs) and treated with drug combinations that are known to cause … NettetInSphero is a global pioneer in 3D cell culture models for in-vitro toxicology and drug discovery using state-of-the-art organ emulating technologies. Liver Disease …
NettetDescription of Human Liver Microtissues. A turnkey screening solution for identifying Hepatotoxic compounds. 3D InSight™ Human Liver Microtissues is the gold standard … Nettet18. okt. 2024 · New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2024 (GLOBE NEWSWIRE ...
NettetA World of Discovery in Every Hanging Drop InSphero is the leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. Headquartered in Zurich, Switzerland with subsidiaries in the USA and Germany, we currently count all of the top 15 global pharmaceutical and cosmetics companies as our … Nettet29. sep. 2015 · InSphero Dr. Randy Strube Director of Global Marketing +1 800-779-7558 ext. 102 [email protected] or Dr. Jan Lichtenberg CEO and Co-Founder …
Nettet26. nov. 2024 · 3D Cell Culture Technology 3D liver models 3D multicellular models 2024 SOT adenoviral transduction animal models AST Body on a Chip Diabetes DILI Drug Discovery embryonic stem cell test …
NettetPharma companies racing to accelerate the drug discovery for chronic liver ... and mechanistic studies. Here's how […] June 29, 2024. Building a Better Model to Detect … hello john jurassic park gifNettetGravityPLUS™ Hanging Drop Plate (“GravityPLUS™ Plate”) and one GravityTRAP™ Plate. InSphero uses this system for routine large-scale production of assay-ready microtissues. For a list of available 3D microtissue models for efficacy and toxicology studies, please refer to 3D InSight™ Microtissues on our website at www.insphero.com. hello joeNettetInSphero assay-ready organoids are engineered and certified for use in critical drug development applications and validated to ensure uniform size, robust functionality, and … hello johannesburgNettetFrancisco is the VP of Liver Discovery at InSphero since 2024. He obtained a PhD in molecular biology at the Pasteur Institute in Paris. He has been trained for 6 years as postdoctoral fellow at Harvard University/Dana Farber Cancer Institute and Karolinska Institute where he focused on the molecular basis of metabolic disorders. He was … hello john blaqNettet23. nov. 2024 · Non-alcoholic steatohepatitis (NASH) is a progressive and severe liver disease, characterized by lipid accumulation, inflammation, and downstream fibrosis. Despite its increasing prevalence, there is no approved treatment yet available for patients. This has been at least partially due to the lack o … hello john doeNettet24. aug. 2024 · InSphero Appoints Prof. Dr. Francisco Verdeguer as VP, Head of Liver Discovery Group. InSphero, the leading biotech for the development of complex 3D … hello joe thomasNettet21. jan. 2016 · In vitro models continuously evolve to more closely mimic and predict biological responses of living organisms. Just in the past years many novel three dimensional (3D) organotypic models, which … hello john et al